FUNDAMENTAL AND CLINICAL STUDIES ON CEFUROXIME AXETIL

• Published in: CHEMOTHERAPY Vol. 34; no. Supplement5; pp. 496 - 499
• Main Authors: OI, SATOSHI, TOTSUKA, KYOICHI, KUMADA, TEPPEI, SHIMIZU, KIHACHIRO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1986
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.34.Supplement5_496

The fundamental and clinical studies were performed on Cefuroxime axetil (CXM-AX, SN 407), a newly developed oral cephalosporin. After a single oral dose of 500mg of CXM-AX in two healthy male volunteers in the fasting state, the blood levels of CXM were 3.12 and 4.17μg/ml respectively at one hour, and reached the peaks of 3.87 and 5.59μg/ml at 1.5-2 hours. The serum half-lives (T1/2) were 1.89 and 1.23 hours, respectively. The 0-6 hr urinary recovery rates were 40.7% and 17.0%. Clinical efficacy of CXM-AX was evaluated in 4 cases, i.e.3 of acute bronchitis and 1 of acute cystitis. The causative organism was E. coli in the acute cystitis case, but was not isolated from the acute bronchitis cases. CXM-AX was administered in the dose levels of 250mg twice or three times daily. The clinical efficacy was good in all the cases. No noteworthy adverse events or abnormal laboratory findings were noted.